Opinion

Video

Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL

Author(s):

Catherine C. Coombs, MD,Bita Fakhri, MD, MPH

Focusing on the CLL13 and CLL14 studies, Bita Fakhri, MD, MPH, provides insights on the role of venetoclax-based first-line combination strategies and factors that inform treatment selection.

Video content above is prompted by the following questions:

  • Discuss the role of venetoclax-based first-line (1L) combination treatment strategies.
    • How do you select patients for venetoclax + rituximab vs venetoclax + obinutuzumab vs venetoclax + ibrutinib?

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Related Content
FDA
June 11th 2025

FDA Approves Tablet Formulation of Zanubrutinib for B-Cell Malignancies

Anna C. Pavlick, BSN, MSc, DO, MBA, professor, medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine; founding director, Cutaneous Oncology Program, Weill Cornell Medicine and NewYork-Presbyterian
May 5th 2025

RP1 Plus Nivolumab Delivers Durable Responses in PD-1–Exposed Melanoma: With Anna C. Pavlick, BSN, MSc, DO, MBA

CLL/SLL | Image Credit: ©Brighting Collection - stock.adobe.com
May 31st 2025

Zanubrutinib Plus Venetoclax Yields High Response Rates in Treatment-Naive CLL/SLL

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, the Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Susan M. O'Brien, MD, associate director, Clinical Science, Chao Family Comprehensive Cancer Center, medical director, Sue & Ralph Stern Center for Clinical Trials & Research, professor, medicine, Division of Hematology/Oncology, University of California Irvine School of Medicine
December 31st 2024

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

CLL/SLL | Image Credit: © Mikkel – stock.adobe.com
May 25th 2025

Zanubrutinib Yields High Response Rates in Japanese Patients With CLL/SLL and Waldenström Macroglobulinemia

The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.
May 18th 2025

Five Under 5: Top Oncology Videos for the Week of 5/11